New study raises questions about antifungal treatments during pregnancy
A new study suggests that common antifungal medicines used during pregnancy may be associated with changes in hormone production in the foetus. However, the researchers cannot yet say whether the differences observed have consequences for the children later in life.
Studies including analyses of adrenal tissue samples from rats, such as this one, have prompted researchers to call for further research into the safety of antifungal use during pregnancy. Photo: DTU National Food Institute
Tuesday 06 October 2026
Lene Hundborg Koss
Many pregnant women develop fungal infections, which are often treated with widely used azole-based antifungal medicines.
A new study involving researchers from the DTU National Food Institute and Copenhagen University Hospital (Rigshospitalet) suggests that the use of these medicines during pregnancy may be associated with changes in fetal hormone production, with effects persisting in children after birth.
However, the researchers do not yet know whether the differences they have identified will affect the children’s health or their ability to have children later in life.
The researchers analysed data from 589 Danish mother–child pairs. Their findings were supported by laboratory experiments using human fetal adrenal tissue and studies in pregnant rats, in which the researchers examined both blood and adrenal tissue from the rat fetuses.
The study found that children whose mothers used antifungal medicines during pregnancy had altered levels of adrenal hormones three months after birth.
“It is striking that the use of azole-based antifungals during pregnancy appears to affect adrenal hormone levels in children long after birth. Although the hormone levels remained within the normal range, the results suggest that fetal development may have been affected,” says Professor Terje Svingen from the DTU National Food Institute.
Adrenal hormones help regulate many functions in the body, including glucose metabolism, blood pressure, immune function, as well as growth and reproductive development.
Gylli Mola, researcher and medical doctor at Rigshospitalet, elaborates:
“This is particularly noteworthy because the treatments were primarily over-the-counter topical preparations, such as creams and vaginal tablets, which have traditionally been considered safe to use during pregnancy.”
The researchers therefore believe that the safety of widely used antifungals during pregnancy warrants further investigation.
Monica Kam Draskau, a researcher at the DTU National Food Institute, has worked on the analyses of the experimental studies.
“The fact that the findings in children are supported by results from both human fetal adrenal tissue and experiments in rats strengthens our hypothesis that there is a link with the use of azole-based antifungal medicines,” she says.
The study cannot directly establish that azole-based antifungal medicines cause the hormonal changes observed in children, nor can the researchers conclude from the study that commonly used antifungal medicines are harmful to children. However, the results highlight the need for further research into the safety of widely used antifungals during pregnancy.
The research is part of the MERLON research project and was funded by the Danish Environmental Protection Agency through the Danish Centre on Endocrine Disrupters (CeHoS), with additional support from the Rigshospitalet Research Council. IRSET in France was a partner in the study.
